Shares of IM Cannabis Corp (NASDAQ:IMCC) tumbled 18.6% in premarket trading on Wednesday after the company disclosed terms of a registered direct offering priced at a notable discount to market.
The medical cannabis firm said it has entered into securities purchase agreements to sell 655,000 common shares at a price of $2.00 per share. The placement is expected to produce gross proceeds of approximately $1.31 million before transaction expenses and is slated to close on or about September 24, 2026.
In announcing the offering, IM Cannabis said it is relying on exemptions from formal valuation and minority shareholder approval requirements under Multilateral Instrument 61-101. That exemption is based on the company’s asserted financial hardship and requires both a board determination and the concurrence of at least two-thirds of independent directors that the company is in serious financial difficulty and that the offering is intended to improve its financial position.
The company also disclosed that one or more purchasers in the offering may be related parties. IM Cannabis operates in Israel and Germany and indicated that net proceeds will be used for working capital and general corporate purposes, which may include evaluating potential additional business opportunities.
The offering is being done pursuant to an effective shelf registration statement on Form F-3, which the Securities and Exchange Commission declared effective on July 9, 2025. The company did not provide additional comment beyond the filing details and the expected closing date.
The move follows the company’s decision to pursue immediate capital through a registered direct sale of common stock, a step that coincided with the sharp premarket share decline. The offering’s discounted pricing and the reliance on financial hardship exemptions under MI 61-101 were highlighted in the disclosure filings accompanying the placement.
Investors and market participants will likely watch for confirmation of the offering close around the projected September 24, 2026 date and for any further statements from the company on the use of proceeds and potential related-party participation.